BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13(6): 837-844 [PMID: 17352011 DOI: 10.3748/wjg.v13.i6.837]
URL: https://www.wjgnet.com/1007-9327/full/v13/i6/837.htm
(0) (0) (5087) (136)
Number Citing Articles
1
Ciaran E. Fealy, Jacob M. Haus, Thomas P. J. Solomon, Mangesh Pagadala, Chris A. Flask, Arthur J. McCullough, John P. Kirwan. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. Journal of Applied Physiology 2012; 113(1) doi: 10.1152/japplphysiol.00127.2012
2
Ludmila V. Topchieva, Irina V. Kurbatova, Olga P. Dudanova, Alina V. Vasileva, Galina A. Zhulai. Immune cell balance as potential biomarker of progressing non-alcoholic fatty liver disease. Genes & Cells 2024; 19(1) doi: 10.17816/gc610252
3
Carolina F. M. G. Pimentel, Zhenghui G. Jiang, Takeshi Otsubo, Linda Feldbrügge, Tracy L. Challies, Imad Nasser, Simon Robson, Nezam Afdhal, Michelle Lai. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Digestive Diseases and Sciences 2016; 61(3) doi: 10.1007/s10620-015-3916-1
4
Yusuke Kawamura, Kenji Ikeda, Yasuji Arase, Shunichiro Fujiyama, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Internal Medicine 2017; 56(12) doi: 10.2169/internalmedicine.56.7830
5
Zixiong Zhou, Jong Won Kim, Jing Zhao, Jing Qi, Seong Jin Choi, Chae Woong Lim, Moo-Yeol Lee, Kyuhong Lee, Bumseok Kim. Treatment of cigarette smoke extract and condensate differentially potentiates palmitic acid-induced lipotoxicity and steatohepatitis in vitro. Toxicology in Vitro 2018; 52 doi: 10.1016/j.tiv.2018.05.017
6
Fatih Eren, Ramazan Kurt, Fatih Ermis, Ozlen Atug, Nese Imeryuz, Yusuf Yilmaz. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry 2012; 45(9) doi: 10.1016/j.clinbiochem.2012.03.019
7
Lei He, Linfeng Deng, Quan Zhang, Jianli Guo, Jinan Zhou, Wenjian Song, Fahu Yuan. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. BioMed Research International 2017; 2017 doi: 10.1155/2017/9729107
8
Cristina Macía, Jose Loureiro, Isabel Campos-Varela, Ihab Abdulkader, Esteban Otero, Evaristo Varo, Santiago Tomé, Arturo Gonzalez-Quintela, Ned Snyder. Time-Course Changes of Serum Keratin Concentrations after Liver Transplantation: Contrasting Results of Keratin-18 and Keratin-19 Fragments. Case Reports in Hepatology 2020; 2020 doi: 10.1155/2020/8895435
9
Sercan Kaya, Murat Boydak, Mesut Aydin, İbrahim Aras. Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease*. Biotechnic & Histochemistry 2024; 99(6) doi: 10.1080/10520295.2024.2385011
10
Constantinos Simopoulos, Alexandra K Tsaroucha, Byron Asimakopoulos, Alexandra Giatromanolaki, Paschalis Gavriilidis, Alexandros Polychronidis, Anastasios Karayiannakis. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective study. BMC Gastroenterology 2008; 8(1) doi: 10.1186/1471-230X-8-14
11
Yvonne Alt, Anna Grimm, Liesa Schlegel, Annette Grambihler, Jens M. Kittner, Jörg Wiltink, Peter R. Galle, Marcus A. Wörns, Jörn M. Schattenberg, Matias A Avila. The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. PLOS ONE 2016; 11(3) doi: 10.1371/journal.pone.0151200
12
Arun Sanyal, Kenneth Cusi, Mark L Hartman, Shuyu Zhang, Edward J Bastyr, Juliana M Bue-Valleskey, Annette M Chang, Axel Haupt, Scott J Jacober, Robert J Konrad, Qianyi Zhang, Byron J Hoogwerf. Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. Journal of Investigative Medicine 2018; 66(3) doi: 10.1136/jim-2017-000609
13
Naim Alkhouri, Christine Carter-Kent, Ariel E Feldstein. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Review of Gastroenterology & Hepatology 2011; 5(2) doi: 10.1586/egh.11.6
14
Leon A ADAMS, Ariel E FELDSTEIN. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. Journal of Digestive Diseases 2011; 12(1) doi: 10.1111/j.1751-2980.2010.00471.x
15
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology 2008; 134(6) doi: 10.1053/j.gastro.2008.02.077
16
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016;  doi: 10.1007/978-94-007-7742-2_32-1
17
Zobair M. Younossi, Mohammed Jarrar, Clare Nugent, Manpreet Randhawa, Mariam Afendy, Maria Stepanova, Nila Rafiq, Zachary Goodman, Vikas Chandhoke, Ancha Baranova. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). Obesity Surgery 2008; 18(11) doi: 10.1007/s11695-008-9506-y
18
N. J. BARSHOP, C. B. SIRLIN, J. B. SCHWIMMER, J. E. LAVINE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008; 28(1) doi: 10.1111/j.1365-2036.2008.03703.x
19
Fataneh Amidi, Barbara A. French, David Chung, Charles H. Halsted, Valentina Medici, Samuel W. French. M-30 and 4HNE are sequestered in different aggresomesin the same hepatocytes. Experimental and Molecular Pathology 2007; 83(3) doi: 10.1016/j.yexmp.2007.09.001
20
Giovanni Musso, Roberto Gambino, Giovanni Pacini, Franco De Michieli, Maurizio Cassader. Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. The American Journal of Clinical Nutrition 2009; 89(2) doi: 10.3945/ajcn.2008.26720
21
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017;  doi: 10.1007/978-94-007-7675-3_32
22
Y. YILMAZ. Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology & Therapeutics 2009; 30(11-12) doi: 10.1111/j.1365-2036.2009.04148.x
23
Krishna Sumanth Nallagangula, Shashidhar Kurpad Nagaraj, Lakshmaiah Venkataswamy, Muninarayana Chandrappa. Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression. Future Science OA 2018; 4(1) doi: 10.4155/fsoa-2017-0083
24
Franck Brouillard, Janine Fritsch, Aleksander Edelman, Mario Ollero. Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathology. PROTEOMICS – Clinical Applications 2008; 2(2) doi: 10.1002/prca.200780018
25
J. Shen, H. L.‐Y. Chan, G. L.‐H. Wong, A. W.‐H. Chan, P. C.‐L. Choi, H.‐Y. Chan, A. M.‐L. Chim, D. K.‐W. Yeung, J. Yu, W. C.‐W. Chu, V. W.‐S. Wong. Assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 2012; 36(11-12) doi: 10.1111/apt.12091
26
Nafiseh Esmaeil, Behjat Moayedi, Marjan Gharagozloo, Mohamad Reza Maracy. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, In Patients with β-Thalassemia Major. Hemoglobin 2013; 37(4) doi: 10.3109/03630269.2013.790828
27
Yusuf Yilmaz, Ramazan Kurt, Cem Kalayci. Apoptosis in Nonalcoholic Steatohepatitis With Normal Aminotransferase Values: Zooming in on Cytokeratin 18 Fragments. Biomarkers in Medicine 2010; 4(5) doi: 10.2217/bmm.10.65
28
J. Shen, V. W.‐S. Wong. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitis – authors’ reply. Alimentary Pharmacology & Therapeutics 2013; 37(2) doi: 10.1111/apt.12156
29
Michael H. Miller, Michael A. J. Ferguson, John F. Dillon. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver International 2011; 31(4) doi: 10.1111/j.1478-3231.2011.02451.x
30
Yusuf Yilmaz. Cytokeratins in hepatitis. Clinica Chimica Acta 2011; 412(23-24) doi: 10.1016/j.cca.2011.09.002
31
Leon A Adams, Ariel E Feldstein. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Review of Gastroenterology & Hepatology 2010; 4(5) doi: 10.1586/egh.10.56
32
Naim Alkhouri, Anna Alisi, Vera Okwu, Ammar Matloob, Federica Ferrari, Annalisa Crudele, Rita De Vito, Rocio Lopez, Ariel E. Feldstein, Valerio Nobili. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2015; 60(8) doi: 10.1007/s10620-015-3614-z
33
Ying Shi, Shihui Sun, Yali Liu, Junfeng Li, Tong Zhang, Hao Wu, Xinyue Chen, Dexi Chen, Yusen Zhou. Keratin 18 phosphorylation as a progression marker of chronic hepatitis B. Virology Journal 2010; 7(1) doi: 10.1186/1743-422X-7-70
34
Engin Ulukaya, Ceyda Acilan, Yusuf Yilmaz. Apoptosis: why and how does it occur in biology?. Cell Biochemistry and Function 2011; 29(6) doi: 10.1002/cbf.1774
35
Salvatore Petta, Aurora Giannetti. Non-Alcoholic Fatty Liver Disease. 2020;  doi: 10.1007/978-3-319-95828-6_13
36
Ciro Celsa, Grazia Pennisi, Federica Spatola, Aurora Giannetti, Salvatore Petta. NAFLD and NASH. 2020;  doi: 10.1007/978-3-030-37173-9_6
37
Yasar Colak, Ebubekir Senates, Oguzhan Ozturk, Yusuf Yilmaz, Ebru Zemheri, Feruze Yilmaz Enc, Celal Ulasoglu, Sebahat Aksaray, Sabriye Gulcin Bozbeyoglu, Safak Kiziltas, Oya Ovunc Kurdas, Ilyas Tuncer. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2012; 24(3) doi: 10.1097/MEG.0b013e32834e8041
38
Jenny Lee, Yasaman Vali, Jérôme Boursier, Kevin Duffin, Joanne Verheij, M. Julia Brosnan, Koos Zwinderman, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad Hadi Zafarmand, Pavel Strnad. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLOS ONE 2020; 15(9) doi: 10.1371/journal.pone.0238717
39
Davide Festi, Ramona Schiumerini, Giovanni Marasco, Eleonora Scaioli, Francesca Pasqui, Antonio Colecchia. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015; 9(8) doi: 10.1586/17474124.2015.1049155
40
Vaishali Patel, Arun J. Sanyal, Richard Sterling. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2) doi: 10.1016/j.cld.2015.10.006
41
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156(5) doi: 10.1053/j.gastro.2018.12.036
42
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments. Obesity Surgery 2008; 18(11) doi: 10.1007/s11695-008-9639-z
43
Julien Calderaro, Elie Serge Zafrani. Stéatopathie hépatique non alcoolique. Annales de Pathologie 2010; 30(6) doi: 10.1016/j.annpat.2010.10.002
44
Yusuf Yilmaz, Fatih Eren. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta 2012; 414 doi: 10.1016/j.cca.2012.08.005
45
Scott C. Beeman, Joel R. Garbow. Imaging and Metabolism. 2018;  doi: 10.1007/978-3-319-61401-4_10
46
Mayumi TABUCHI, Kayoko TOMIOKA, Takayo KAWAKAMI, Yasuko MURAKAMI, Makoto HIRAMATSU, Tatsuya ITOSHIMA, Shiori SUGAWARA, Aiko KAWASHIMA, Misako OKITA, Ikuyo TSUKAMOTO. Serum Cytokeratin 18 M30 Antigen Level and Its Correlation with Nutritional Parameters in Middle-Aged Japanese Males with Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Nutritional Science and Vitaminology 2010; 56(5) doi: 10.3177/jnsv.56.271
47
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. Gastroenterología y Hepatología (English Edition) 2017; 40(6) doi: 10.1016/j.gastre.2017.02.003
48
Jun Yu, Jiayun Shen, Ting Ting Sun, Xiang Zhang, Nathalie Wong. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Seminars in Cancer Biology 2013; 23(6) doi: 10.1016/j.semcancer.2013.07.003
49
Billur Canbakan, Hakan Senturk, Mustafa Canbakan, Tayfur Toptas, Omur Tabak, Huriye Balci, Vakur Olgac, Gulsen Ozbay. Is Alanine Aminotransferase Level a Surrogate Biomarker of Hepatic Apoptosis in Nonalcoholic Fatty Liver Disease?. Biomarkers in Medicine 2010; 4(2) doi: 10.2217/bmm.09.88
50
Mariana V. Machado, Helena Cortez-Pinto. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology 2013; 58(5) doi: 10.1016/j.jhep.2012.11.021
51
Junzhao Ye, Jiaming Lai, Ling Luo, Ting Zhou, Yanhong Sun, Bihui Zhong. Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis. Clinica Chimica Acta 2025; 569 doi: 10.1016/j.cca.2025.120147
52
Michael Fuchs, Arun J. Sanyal. The Liver. 2009;  doi: 10.1002/9780470747919.ch45
53
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena. Gastroenterología y Hepatología 2017; 40(6) doi: 10.1016/j.gastrohep.2017.02.009
54
Jacquelyn J. Maher, Pablo Leon, James C. Ryan. Beyond insulin resistance. Hepatology 2008; 48(2) doi: 10.1002/hep.22399
55
Nora Anderson, Jürgen Borlak. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews 2008; 60(3) doi: 10.1124/pr.108.00001
56
Tunay Senturk, Ali Aydinlar, Yusuf Yilmaz, Arzu Yilmaztepe Oral, Osman Ozdabakoglu, Engin Ulukaya. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. Coronary Artery Disease 2009; 20(8) doi: 10.1097/MCA.0b013e328330d56a
57
Julia Kälsch, Lars P. Bechmann, Hagen Kälsch, Martin Schlattjan, Jochen Erhard, Guido Gerken, Ali Canbay. Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. Journal of Nutrition and Metabolism 2011; 2011 doi: 10.1155/2011/369168
58
Pamela Valva, Paola Casciato, Carol Lezama, Marcela Galoppo, Adrián Gadano, Omar Galdame, María Cristina Galoppo, Eduardo Mullen, Elena De Matteo, María Victoria Preciado, Ravi Jhaveri. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children. PLoS ONE 2013; 8(1) doi: 10.1371/journal.pone.0053519
59
K Widhalm, E Ghods. Nonalcoholic fatty liver disease: a challenge for pediatricians. International Journal of Obesity 2010; 34(10) doi: 10.1038/ijo.2010.185
60
Briohny W. Smith, Leon A. Adams. Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 2011; 48(3) doi: 10.3109/10408363.2011.596521
61
Wah-Kheong Chan, Pavai Sthaneshwar, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Anna Alisi. Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers. PLoS ONE 2014; 9(9) doi: 10.1371/journal.pone.0105903
62
Pamela Valva, Daniela A Ríos, Elena De Matteo, Maria V Preciado. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World Journal of Gastroenterology 2016; 22(4): 1367-1381 doi: 10.3748/wjg.v22.i4.1367
63
Alastair Greystoke, Andrew Hughes, Malcolm Ranson, Caroline Dive, Jeff Cummings, Tim Ward. Serum biomarkers of apoptosis. European Journal of Cancer Supplements 2007; 5(5) doi: 10.1016/S1359-6349(07)70032-0
64
Rabia Ergelen, Umit Akyuz, Yucel Aydin, Fatih Eren, Yusuf Yilmaz. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015; 27(6) doi: 10.1097/MEG.0000000000000342
65
Sophia Heinrich, Thomas Austgen, Darko Castven, Moritz Hess, Christian Labenz, Martha Kirstein, Carolin Zimpel, Lena Stockhoff, Benjamin Maasoumy, Bernd Heinrich, Hans Heinrich Wedemeyer, Peter Robert Galle, Harald Binder, Marc Nguyen‐Tat, Jens Uwe Marquardt. Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome. United European Gastroenterology Journal 2023; 11(1) doi: 10.1002/ueg2.12337
66
Naim Alkhouri, Ariel E. Feldstein. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.01.013
67
Andrew J Fowell, Kirsty Fancey, Karen Gamble, Kelly Bicknell, Joanna K Dowman, Paul Howden, Richard J Aspinall. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterology 2021; 12(2) doi: 10.1136/flgastro-2019-101304
68
Maurizio Soresi, Lydia Giannitrapani, Melchiorre Cervello, Anna Licata, Giuseppe Montalto. Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology 2014; 20(48): 18131-18150 doi: 10.3748/wjg.v20.i48.18131
69
Mohammad Safarian, Sepideh Mohammadpour, Mojtaba Shafiee, Azita Ganji, Anvar Soleimani, Mohsen Nematy, Ali Bahari. Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(2) doi: 10.1016/j.dsx.2019.01.005
70
Arturo Gonzalez‐Quintela, Santiago Tomé, Carmen Fernandez‐Merino, Jesus Rey, Luis Meijide, Francisco Gude. Synergistic Effect of Alcohol Consumption and Body Mass on Serum Concentrations of Cytokeratin‐18. Alcoholism: Clinical and Experimental Research 2011; 35(12) doi: 10.1111/j.1530-0277.2011.01570.x
71
David E. Amacher. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014; 19(7) doi: 10.3109/1354750X.2014.958535
72
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 2011; 43(8) doi: 10.3109/07853890.2010.518623
73
Yusuf Yilmaz, Fatih Eren. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2014; 26(11) doi: 10.1097/MEG.0000000000000184
74
Diana Joka, Kristin Wahl, Sarah Moeller, Jerome Schlue, Bernhard Vaske, Matthias J. Bahr, Michael P. Manns, Klaus Schulze-Osthoff, Heike Bantel. Prospective Biopsy-Controlled Evaluation of Cell Death Biomarkers for Prediction of Liver Fibrosis and Nonalcoholic Steatohepatitis. Hepatology 2012; 55(2) doi: 10.1002/hep.24734
75
J. K. Dowman, J. W. Tomlinson, P. N. Newsome. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2011; 33(5) doi: 10.1111/j.1365-2036.2010.04556.x
76
Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports 2024; 13(3) doi: 10.1007/s13679-024-00574-z
77
M. Civera, A. Urios, M. L. Garcia‐Torres, J. Ortega, J. Martinez‐Valls, N. Cassinello, J. A. del Olmo, A. Ferrandez, J. M. Rodrigo, C. Montoliu. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes/Metabolism Research and Reviews 2010; 26(3) doi: 10.1002/dmrr.1070
78
Kai Liu, Jinli Lou, Tao Wen, Jiming Yin, Bin Xu, Wei Ding, Anna Wang, Daojie Liu, Chao Zhang, Dexi Chen, Ning Li. Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM‐induced autophagy or BAX. Liver International 2013; 33(10) doi: 10.1111/liv.12238
79
Jinwen Chen, Jian Hu, Jialin Zhuang, Zhong Li, Se Peng, Xiaoting Huang, Jialing Zhuang. Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis. Journal of Clinical Laboratory Analysis 2025; 39(8) doi: 10.1002/jcla.70034
80
Ariel E Feldstein, Naim Alkhouri, Rita De Vito, Anna Alisi, Rocio Lopez, Valerio Nobili. Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. American Journal of Gastroenterology 2013; 108(9) doi: 10.1038/ajg.2013.168
81
Pamela Valva, Daniela Rios, Paola Casciato, Adrián Gadano, Omar Galdame, Eduardo Mullen, Gustavo Bertot, Elena de Matteo, María V. Preciado. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina. European Journal of Gastroenterology & Hepatology 2018; 30(6) doi: 10.1097/MEG.0000000000001079
82
María Rubio-Murillo, Alejandro Rodríguez-Martínez. NAFLD and NASH. 2020;  doi: 10.1007/978-3-030-37173-9_5
83
Pamela Valva, Elena De Matteo, María C. Galoppo, María I. Gismondi, María V. Preciado. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. Journal of Medical Virology 2010; 82(6) doi: 10.1002/jmv.21699
84
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017;  doi: 10.1007/978-94-007-7675-3_5
85
Eugenia Tsai, Tai-Ping Lee. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clinics in Liver Disease 2018; 22(1) doi: 10.1016/j.cld.2017.08.004
86
Raj Vuppalanchi, Naga Chalasani. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2009; 49(1) doi: 10.1002/hep.22603
87
Masaru Tsutsui, Naoki Tanaka, Masatomo Kawakubo, Yo Sheena, Akira Horiuchi, Michiharu Komatsu, Tadanobu Nagaya, Satoru Joshita, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Toshifumi Aoyama, Eiji Tanaka, Kenji Sano. Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology 2010; 44(6) doi: 10.1097/MCG.0b013e3181bdefe2
88
Jing Chen, Yueyong Zhu, Qi Zheng, Jiaji Jiang. Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis. Hepatology Research 2014; 44(8) doi: 10.1111/hepr.12197
89
Y. Yilmaz. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2013; 37(2) doi: 10.1111/apt.12142
90
Bryan D. Maliken, James E. Nelson, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Kris V. Kowdley. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013; 57(5) doi: 10.1002/hep.26238
91
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016;  doi: 10.1007/978-94-007-7742-2_5-1
92
Dulshan Jayasekera, Phillipp Hartmann. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease. World Journal of Hepatology 2023; 15(5): 609-640 doi: 10.4254/wjh.v15.i5.609
93
Hazem Abd-Elgawad, Nashwa Abu-Elsaad, Amr El-Karef, Tarek Ibrahim. Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Canadian Journal of Physiology and Pharmacology 2016; 94(7) doi: 10.1139/cjpp-2016-0001
94
Sezgin Ulukaya, Engin Ulukaya, Isik Alper, Arzu Yilmaztepe‐Oral, Murat Kilic. Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantation. Clinical Transplantation 2010; 24(6) doi: 10.1111/j.1399-0012.2009.01177.x
95
Fatih Eren, Yusuf Yilmaz, Sukran Kose, Filiz Ture Ozdemir, Oya Yonal, Ramazan Kurt, Osman Ozdogan, Erol Avsar. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clinica Chimica Acta 2010; 411(23-24) doi: 10.1016/j.cca.2010.08.035
96
Joanne R. Morling, Jonathan A. Fallowfield, Rachel M. Williamson, Lisa D. Nee, Andrew P. Jackson, Stephen Glancy, Rebecca M. Reynolds, Peter C. Hayes, Indra N. Guha, Mark W. J. Strachan, Jackie F. Price. Non‐invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver International 2014; 34(8) doi: 10.1111/liv.12385
97
Ariel E. Feldstein, Anna Wieckowska, Rocio A. Lopez, Yao-Chang Liu, Nizar N. Zein, Arthur J. McCullough. Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis. Hepatology 2009; 50(4) doi: 10.1002/hep.23050
98
Jeffrey R. Lewis, Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update. Digestive Diseases and Sciences 2010; 55(3) doi: 10.1007/s10620-009-1081-0
99
Danielle Adebayo, Vincenzo Morabito, Fausto Andreola, Giulia Pieri, Tu‐Vin Luong, Amar Dhillon, Rajeshwar Mookerjee, Rajiv Jalan. Mechanism of cell death in acute‐on‐chronic liver failure: a clinico‐pathologic‐biomarker study. Liver International 2015; 35(12) doi: 10.1111/liv.12850
100
Miwa Kawanaka, Ken Nishino, Jun Nakamura, Noriyo Urata, Takahito Oka, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Annals of Hepatology 2015; 14(6) doi: 10.5604/16652681.1171767
101
Ankita Singh, Vipul Ranjan, Rina Das, Karun Bhatti, Dinesh Kumar Mehta, Ram Mohan Chidurala. Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How Laudable are These Tools?. Current Chemical Biology 2021; 15(2) doi: 10.2174/2212796814999201111204639
102
Shiori Sugawara, Takemi Akahane, Kennichi Fukui, Ikuyo Tsukamoto. Association of Serum CK18 M30 Antigen Level with Food Intake in Middle-aged Japanese Men. Nippon Eiyo Shokuryo Gakkaishi 2014; 67(3) doi: 10.4327/jsnfs.67.127
103
Mesbah Uddin Ahmed. Association of Serum Cytokeratin-18 Fragment Concentration in Patients with Different Types of Nonalcoholic Fatty Liver Disease. Gastroenterology & Hepatology : Open Access 2015; 2(2) doi: 10.15406/ghoa.2015.02.00037
104
Steven J. Potts, Johanna K. DiStefano. Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Methods in Pharmacology and Toxicology 2014;  doi: 10.1007/7653_2014_29
105
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels #. Hepatology 2009; 49(2) doi: 10.1002/hep.22691
106
Henryk Dancygier. Clinical Hepatology. 2010;  doi: 10.1007/978-3-642-04519-6_35
107
Luca Maccioni, Yves Horsmans, Isabelle Leclercq, Bernd Schnabl, Peter Stärkel. Serum keratin 18‐M65 levels detect progressive forms of alcohol‐associated liver disease in early noncirrhotic stages. Alcohol: Clinical and Experimental Research 2023; 47(6) doi: 10.1111/acer.15081
108
Vlad Ratziu, Laurence Martin, Larysa Fedchuk, Thierry Poynard. Can Nonalcoholic Steatohepatitis be Diagnosed Without Liver Biopsy?. Biomarkers in Medicine 2009; 3(4) doi: 10.2217/bmm.09.36
109
R. Kwok, Y.‐K. Tse, G. L.‐H. Wong, Y. Ha, A. U. Lee, M. C. Ngu, H. L.‐Y. Chan, V. W.‐S. Wong. Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments. Alimentary Pharmacology & Therapeutics 2014; 39(3) doi: 10.1111/apt.12569
110
Guofeng Ding, Zhi Li, Lei Zhang, Hui Ma, Hui Li. Circulating full‐length cytokeratin 18 for predicting prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure patients with lamivudine treatment. Hepatology Research 2016; 46(4) doi: 10.1111/hepr.12549
111
Gamal Shiha, Nasser Mousa. Liver Diseases. 2020;  doi: 10.1007/978-3-030-24432-3_36
112
Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57(1) doi: 10.1002/hep.26030
113
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 2011; 9(3) doi: 10.1586/erc.11.15
114
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology 2011; 26(s1) doi: 10.1111/j.1440-1746.2010.06547.x
115
Dina G. Tiniakos, George V. Papatheodoridis. Serum Markers of Hepatocyte Apoptosis: Current Terminology and Predictability in Clinical Practice. Hepatology 2010; 51(2) doi: 10.1002/hep.23251
116
Angeliki Papachristodoulou, Dimitrios Kavvadas, Athanasios Karamitsos, Theodora Papamitsou, Maria Chatzidimitriou, Antonia Sioga. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?. Pediatric Reports 2021; 13(2) doi: 10.3390/pediatric13020039
117
M. H. Miller, J. F. Dillon. Commentary: assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 2013; 37(2) doi: 10.1111/apt.12134
118
Pauline Verhaegh, Roisin Bavalia, Bjorn Winkens, Ad Masclee, Daisy Jonkers, Ger Koek. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018; 16(6) doi: 10.1016/j.cgh.2017.08.024
119
Steven G Pearce, Nirav C Thosani, Jen-Jung Pan. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-7
120
Zeynep Hünkerler, Tülay Köken, Buğra Koca, Ahmet Kahraman. Role of Uremic Toxins on Apoptosis With Varying Periods of Hemodialysis. Therapeutic Apheresis and Dialysis 2017; 21(1) doi: 10.1111/1744-9987.12504
121
Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li. Cytokeratin 18 in nonalcoholic fatty liver disease: value and application. Expert Review of Molecular Diagnostics 2024; 24(11) doi: 10.1080/14737159.2024.2413941
122
Ancha Baranova, Zobair M. Younossi. Reply to the Letter to the Editor: “A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments” by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Obesity Surgery 2008; 18(11) doi: 10.1007/s11695-008-9641-5
123
George V. Papatheodoridis, Emilia Hadziyannis, Emmanuel Tsochatzis, Anastasia Georgiou, Georgia Kafiri, Dina G. Tiniakos, Katerina Margariti, Spilios Manolakopoulos, Emanuel K. Manesis, Athanasios J. Archimandritis. Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2010; 44(4) doi: 10.1097/MCG.0b013e3181c0945a
124
A. Gonzalez-Quintela, I. Abdulkader, J. Campos, L. Fernandez-Hernandez, S. Lojo. Serum Levels of Keratin-18 Fragments [Tissue Polypeptide-Specific Antigen (TPS)] Are Correlated with Hepatocyte Apoptosis in Alcoholic Hepatitis. Digestive Diseases and Sciences 2009; 54(3) doi: 10.1007/s10620-008-0371-2
125
Mitchell R. McGill, Hartmut Jaeschke. Drug-induced Liver Injury. Advances in Pharmacology 2019; 85 doi: 10.1016/bs.apha.2019.02.001
126
Iradj Maleki, Mahmood Reza Aminafshari, Tarang Taghvaei, Vahid Hosseini, Alireza Rafiei, Zhila Torabizadeh, Maryam Barzin, Elahe Orang. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014; 20(35): 12566-12573 doi: 10.3748/wjg.v20.i35.12566
127
Helena Cortez-Pinto, Mariana Machado. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2008; 2(2) doi: 10.1586/17474124.2.2.217
128
Karel Dvorak, Jan Stritesky, Jaromir Petrtyl, Libor Vitek, Renata Sroubkova, Martin Lenicek, Vaclav Smid, Martin Haluzik, Radan Bruha, Pavel Strnad. Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study. PLoS ONE 2014; 9(10) doi: 10.1371/journal.pone.0111551
129
Andreas E Kremer, Christian Rust, Peter Eichhorn, Ulrich Beuers, Stefan Holdenrieder. Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Review of Molecular Diagnostics 2009; 9(2) doi: 10.1586/14737159.9.2.139
130
Mikako Obika, Hirofumi Noguchi. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research 2012; 2012 doi: 10.1155/2012/145754
131
Yusuf Yilmaz. “Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18 #. Hepatology 2009; 50(3) doi: 10.1002/hep.23065
132
Matt Cave, Keith Cameron Falkner, Latasha Henry, Brittany Costello, Bonnie Gregory, Craig J. McClain. Serum Cytokeratin 18 and Cytokine Elevations Suggest A High Prevalence of Occupational Liver Disease in Highly Exposed Elastomer/Polymer Workers. Journal of Occupational & Environmental Medicine 2011; 53(10) doi: 10.1097/JOM.0b013e31822cfd68
133
S Lefere, F Van de Velde, L Devisscher, M Bekaert, S Raevens, X Verhelst, Y Van Nieuwenhove, M Praet, A Hoorens, C Van Steenkiste, H Van Vlierberghe, B Lapauw, A Geerts. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. International Journal of Obesity 2017; 41(8) doi: 10.1038/ijo.2017.102
134
Yusuf Yilmaz, Ramazan Kurt. Is M65 Really Better Than M30 as a Biomarker of Hepatic Fibrosis?. Hepatology 2012; 55(2) doi: 10.1002/hep.25520
135
Lei Fu, Nurdan Guldiken, Katharina Remih, Anna Sophie Karl, Christian Preisinger, Pavel Strnad. Serum/Plasma Proteome in Non-Malignant Liver Disease. International Journal of Molecular Sciences 2024; 25(4) doi: 10.3390/ijms25042008
136
Gerald Denk, Ahmed‐Jawid Omary, Florian Paul Reiter, Simon Hohenester, Ralf Wimmer, Stefan Holdenrieder, Christian Rust. Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatology Research 2014; 44(13) doi: 10.1111/hepr.12304
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.